In multiple-drug therapy considerable attention has been focused on drug/drug interactions such as interactions in drug distribution, drug metabolism, drug absorption and receptor binding. [1] [2] [3] [4] Beside drug/drug interactions, we reported the significance of drug/metabolite interaction(s) in the biopharmaceutical fate of a drug in the 1960's. [5] [6] [7] [8] [9] [10] Studenberg and Brouwer have also reported that the metabolites of phenobarbital inhibited the biotransformation of acetaminophen.
Studenberg and Brouwer have also reported that the metabolites of phenobarbital inhibited the biotransformation of acetaminophen. 11) Recently we examined the effects of the concomitant use of N-acetyl-p-aminophenyl O-sulfate (APAPS) [12] [13] [14] [15] and its geometric isomers, 16) 4-hydroxyantipyrine (4-OH), 15, 17) 4-hydroxyantipyrine sulfate, 15, 17) and glutathionesulphonic acid sodium salt (N-(N-g-L-glutamyl-Lb-sulphoalanylglycine sodium salt, GSO 3 Na). 18) Obtained results could be summarized as follows: 1) the tissue-to-plasma concentration ratio (K p ) of acetaminophen was significantly increased in the liver, heart, kidney and brain by the presence of APAPS but not by its geometric isomers 16) ; 2) the K p value of antipyrine in brain and heart after its administration under the concomitant use of 4-OH rose significantly 17) ; 3) the tissue partition coefficient and the permeability clearance to blood-brain barrier (CL BBB ) of antipyrine and thiopental sodium (TPS) increased significantly in the presence of 4-OH 15, 17) ; 4) the K p value of citicoline in the brain also increased in the presence of 4-OH. The concentration of antipyrine in plasma under the steady state decreased with the concomitant use of APAPS, and the K p value of antipyrine in the brain and heart increased significantly. The partition coefficient of antipyrine increased noticeably in the presence of APAPS or acetaminophen 15) ; 5) the K p value of TPS in the liver was specifically enhanced by the concomitant use of GSO 3 Na. It was suggested that the elevation of a lipid solubility (oil water partition coefficient) of TPS by the concomitant use of GSO 3 Na was related to the enhancement of the K p value of TPS. 18) In this paper, the possibility of GSO 3 Na as a biodistribution promoter was examined by its concomitant use with verapamil hydrochloride (verapamil · HCl) or tegafur, which is used as a bioactive drug.
MATERIALS AND METHODS
Materials GSO 3 Na 19, 20) was prepared in our laboratory. 18) Tegafur was kindly supplied by Taiho Pharmaceutical Co., Ltd. (Tokyo, Japan). All chemicals and reagents were commercially available and of analytical grade or better.
Animals Male Wistar rats (220-380 g) (Japan SLC, Inc, Hamamatsu, Japan) were used.
In Vivo Experiments The rats were fasted overnight before use, but allowed free access to water, and were fixed in a dorsal position under urethane anesthesia (900 mg/kg, i.p.). Polyethylene tubing was cannulated into both the left femoral vein and the right femoral artery.
Effect of GSO 3 Na on Plasma Elimination of Verapamil · HCl and Tegafur: After intravenous administration of an initial dose (dose was 1.0 mg/kg for verapamil · HCl or 10 mg/kg for tegafur), GSO 3 Na was constantly infused into the left femoral vein through the cannula to make the plasma concentration steady state (400 mg/ml of GSO 3 Na was used.). One hundred twenty minutes after starting the constant infusion, verapamil · HCl or tegafur was administered from the jugular vein. Blood was continually collected from the right femoral artery. Saline under constant infusion was used as a control.
Examination of Tissue to Plasma Concentration Ratio (K p ): Verapamil · HCl or tegafur was administered from the jugular vein under the steady state of GSO 3 Na or saline. Five minutes after the administration, blood was collected from the abdominal aorta, and the rats were decapitated immediately. In the case of verapamil · HCl, tissue samples of the spleen, kidney, liver, lung, heart and brain were extirpated and homogenized (15000ϫg) in isotonic phosphate buffer (pH 7.4) for 5 min. In the case of tegafur, tissue samples of the spleen, kidney, liver, lung, heart, brain, rectum, colon and stomach were extirpated and homogenized (30000ϫg) in isotonic phosphate buffer (pH 7.4) for 1 min. Five milliliters of ethyl acetate was added to 1 ml of the homogenate and the mixture was shaken for 1 h. After centrifugation (3000 rpm, 10 min and 4°C), 4 ml of the upper layer was collected and evaporated in vacuo. The residue was dissolved in 300 ml of the mobile phase solvent for HPLC measurement.
In Vitro Experiments Protein Binding Experiment: Bovine serum albumin (BSA) was dissolved in saline (final concentration was 100 nmol/ml) and preincubated at 37°C for 2 min. One hundred microliters of the test drug solution in saline (final concentration was 20 mg/ml) was added to 400 ml of the BSA solution and the mixture was incubated at 37°C for 5 min. After incubation, the mixture was immediately ultrafiltrated through ULTRAFREE C3LGC (Japan Millipore Co., Tokyo). The filtrate was diluted with methanol (5-fold volume of the filtrate). The concentration of the free drug (unbound drug) was determined by HPLC measurement. The final concentration was 100-1000 nmol/ml for verapamil · HCl containing 100 nmol/ml of GSO 3 Na or 10-1000 nmol/ml for tegafur containing 100 nmol/ml of GSO 3 Na.
Determination of Partition Coefficient: A mixture of 4 ml of n-octanol saturated phosphate buffer solution (50 mM, pH 7.4) containing 1 mmol/ml of a drug (verapamil · HCl or tegafur) and 1-10 mmol/ml of GSO 3 Na and 4 ml of n-octanol which was saturated with 50 mM phosphate buffer solution was severely shaken at room temperature for 15 min. The mixture was then slowly shaken at 37°C for 2 h. The upper layer (n-octanol layer) was diluted with methanol and the aqueous layer was diluted with purified water. Concentrations of the test compounds were determined by the HPLC measurement.
Determination of Affinity to Tissue: After exsanguination under urethane anesthesia (900 mg/kg, i.p.), fifty-fold volume of saline was added to each organ and the mixture was homogenized. Two hundred microliters of the drug solution (final concentration was 20 mg/ml) was added to 800 ml of this resulting mixture (final concentration was 1 mmol/ml). After shaking for 15 s and centrifugation (12000ϫg and 10 min), the supernatant was immediately ultrafiltrated through ULTRAFREE C3LGC. The filtrate was diluted with a 50-fold volume of methanol (for verapamil · HCl) or a 7-fold volume of purified water (for tegafur) and determined by HPLC measurement. This experiment was performed at low temperature (2-3°C).
Analytical Method The reversed-phase HPLC measurement for the detection of GSO 3 Na, verapamil · HCl 21) and tegafur 22) was performed according to our previous reports. 12, 14, 15, 17, 18) Briefly, a high performance liquid chromatography (LC-10AD, Shimadzu, Kyoto, Japan) was used. This was connected with an Wakopak column (for GSO 3 Na and verapamil · HCl, Wakosil-II 5C18, 4.6 mm i.d.ϫ150 mm, Wako Pure Chemical Industries, Ltd., Osaka, Japan) or with an Inertsil ODS column (for tegafur, average particle size of 5 mm, 4.6 mm i.d.ϫ250 mm, GL Science, Inc., Tokyo) and a UV detector (SPD-10A, Shimadzu, Kyoto) operated at 270 nm (for tegafur) or fluorescence detector (RF-10AXL, Shimadzu, Kyoto) operated at 470 nm (Ex) and 540 nm (Em) for GSO 3 Na or at 280 nm (Ex) and 320 nm (Em) for verapamil · HCl. Mobile phases were 7.5 mM phosphoric acid-acetone (67 : 33, v/v) for verapamil · HCl and 10 mM phosphate buffer solution (pH 5.5)-methanol (85 : 15, v/v) for tegafur. Flow rates were 0.8 ml/min for verapamil · HCl and 1.0 ml /min for tegafur. Injection volumes were 20 ml for both substances. The temperature tested was also 30°C for both of them. Derivatization of GSO 3 Na was reported previously. 18 ) GSO 3 Na, verapamil · HCl and tegafur were separately detected as symmetrical peaks.
Data Analysis Plasma concentrations (C p ) of all drugs after the intravenous administration were fitted to a bi-exponential curve, C p ϭA · exp(Ϫa · t)ϩB · exp(Ϫb · t), by the nonlinear least squares method 23) with a weight of 1/C p . Pharmacokinetic parameters were calculated from the estimated parameters (A, B, a and b) as shown in Fig. 1 .
Tissue-to-plasma concentration ratios (K p ) were estimated under the steady state of GSO 3 Na according to the following equations:
where C t and C p are the concentrations of verapamil · HCl or tegafur in the tissue and in the plasma, respectively; V t is the tissue volume; V i and V e are the intracellular volume and the extracellular volume, respectively. The specific gravities of all tissues were assumed as equal to 1. The K p values of verapamil · HCl and tegafur corrected by inulin space (IS) are shown in Figs. 3 and 4.
Analysis of protein binding was performed using Langmuir and Sandberg-Rosenthal plots. The equation is shown in
where C b is concentration of unbound drug; C f is concentration of bound drug; n is the number of binding sites; P t is total protein mass weight; K d is the dissociation constant, respectively.
As for the determination of partition coefficient, the initial concentration of GSO 3 Na in the aqueous layer and its concentration in the aqueous layer after equilibrium were estimated and the concentration in the n-octanol layer after equilibrium was determined. The equation is shown in P octanol ϭ C octanol /C water ϭ(C o ϪC water )/C water , where C octanol is the concentration of the drug in the n-octanol layer after equilibrium; C water is the concentration of the drug in the aqueous layer after equilibrium; C o is the initial concentration of the drug in the aqueous layer, respectively.
Statistical Analysis Statistical analysis of the pharmacokinetic parameters and tissue-to-plasma concentration ratios were performed by Student's t-test and Tukey's multiple comparison procedure (analysis of variance, ANOVA). In all statistical testing, p values less than 0.05 were considered to be statistically significant. 3 Na Plasma elimination profiles of intravenous bolus administration of verapamil · HCl (1.0 mg/kg) and tegafur (10 mg/kg) under the steady state concentration of GSO 3 Na are shown in Fig. 2 .
RESULTS

Plasma Elimination of Verapamil · HCl and Tegafur after Coadministration with GSO
Pharmacokinetics parameters of verapamil · HCl and tegafur after coadministration of GSO 3 Na were calculated using the pharmacokinetics model ( Fig. 1 ) and are summarized in Table 1 . No significant change with the concomitant use of GSO 3 Na was recognized in any parameter, and plasma elimination of verapamil · HCl and tegafur were not affected by GSO 3 Na. With regard to the pharmacokinetics parameters of the verapamil · HCl, Manitpisitkul and Chiou 24) reported that V dss and CL total of verapamil · HCl were 2.99Ϯ0.57 (l/kg) and 40.4Ϯ10.7 (ml/min/kg), respectively, after its intravenous bolus administration (1.0 mg/kg) in rats. This agreed for the most part with our results.
Effect of GSO 3 Na on the Tissue-to-Plasma Concentration Ratios of Verapamil · HCl and Tegafur The K p values of intravenously administered verapamil · HCl under a steady state concentration of GSO 3 Na are shown in Fig. 3 . The K p value of verapamil · HCl in the lung 5 min after its administration under concomitant use of GSO 3 Na rose significantly about 2 fold, however, this effect disappeared 120 min after administration. No significant change was recognized in other organs.
The K p values of intravenously administered tegafur under a steady state concentration of GSO 3 Na are shown in Fig. 4 . No significant difference in the K p values was recognized in any organs.
Effect of GSO 3 Na on Protein Binding of Verapamil · HCl and Tegafur
Verapamil · HCl is a drug that has high protein binding (93.7%). Langmuir plot of verapamil · HCl to the BSA in the presence of GSO 3 Na showed that the C b /P t value reached a plateau at the range from 100 nmol/ml to 700 nmol/ml of C f (C b /P t value was ca. 3.0). Sandberg-Rosenthal plots of verapamil · HCl to the BSA in the presence of GSO 3 Na are shown in Fig. 5 . The binding parameters in the presence of GSO 3 Na were calculated by a non-linear leastsquares method without the constraint of defined parameters, and the results are shown in Table 2 . No significant difference in the K d values or n · P t values was recognized between the concomitant use and non-use (control) of GSO 3 Na.
Langmuir plot of tegafur to the BSA in the presence of GSO 3 Na showed that C b /P t value increased almost linearly along with elevation of the C f value until 1 mmol/ml (C b /P t was ca. 0.4). The protein binding of tegafur to the BSA in the presence of GSO 3 Na at several concentrations is shown in Fig. 6 . The binding was very low (less than 10%) at every concentration, so that most of the tegafur seemed to exist in blood as a free form and the migration profile into tissues was not greatly affected in the presence of GSO 3 Na. GSO 3 Na are shown in Fig. 7 . The partition coefficient of verapamil · HCl increased along with the elevation of the concentration of GSO 3 Na, and reached a plateau when 5-10 mmol/ml of GSO 3 Na was used. There was no change in the partition coefficient of tegafur, however.
Effects of GSO 3 Na on Apparent Partition Coefficients of Verapamil · HCl and Tegafur
Effects of Verapamil · HCl and Tegafur on Apparent Partition Coefficient of GSO 3 Na Apparent partition coefficients of GSO 3 Na in the presence of verapamil · HCl are shown in Fig. 8 . The partition coefficient of GSO 3 Na decreased significantly compared to that of the control group. Similar partition coefficients of GSO 3 Na in the presence of tegafur are shown in Fig. 9 . In this case almost no difference was found.
Effect of GSO 3 Na on the Affinities of Verapamil · HCl and Tegafur to Tissues Binding ratios of verapamil · HCl and tegafur to several tissues in the presence or absence of GSO 3 Na are shown in Table 3 . As is obvious, no significant effect of GSO 3 Na on the affinities of these substances to tissues was recognized. Results are expressed as the meanϮS.E. (nϭ4).
DISCUSSION
GSO 3 H is a minor metabolite of GSH and is produced on the occasion of the elimination of the radical peroxide. 25) In a previous paper, 18) the effects of the concomitant use of GSO 3 Na on TPS which is a central acting drug and has a moderate lipid solubility were reported. To further study the biodistribution promoter using GSO 3 Na, we here employed verapamil · HCl and tegafur as active drugs instead of TPS. Verapamil · HCl is a peripheral acting drug and a substrate of P-glycoprotein (P-gp), which is related to the selective permeability of BBB. [26] [27] [28] This drug was used here as a typical high lipid soluble drug. Tegafur is a pro-drug of 5-fluorouracil (5-FU) which is a pyrimidine antimetabolite, and transforms to an active substance (5-FUl, FdUMP, FUTP) gradually in an organ. Tegafur must remain at the target position for a long time. It is therefore of great benefit if its biodistribution is specifically promoted by the concomitant use of GSO 3 Na. This drug was used as a typical moderate lipid soluble drug.
With regard to the effect of the concomitant use of GSO 3 Na on plasma elimination profiles of verapamil · HCl and tegafur, neither drug was affected. This result was similar to the case of TPS in the previous paper. 18) On the other hand, tissue-to-plasma concentration ratio (K p ) of verapamil · HCl in the lung 5 min after its administration with the concomitant use of GSO 3 Na rose significantly about 2 fold, although this effect disappeared 120 min after administration. This phenomenon seems to be explained as follows: the stage 5 min after its administration corresponds to a distribution phase (a phase) in the blood pharmacokinetic profile and in the way of distribution. The increase in K p value of verapamil · HCl in the lung was caused by enhancement of its distribution speed resulting from the elevation of its partition coefficient in the presence of GSO 3 Na. On the other hand, the stage 120 min after its administration corresponds to a disappearance phase (b phase) in the blood pharmacokinetic profile and the equilibrium is established. We also assume that the lack of effect on the K p value of verapamil · HCl in the lung 120 min after its administration with the concomitant use of GSO 3 Na means that elevation of the partition coefficient of verapamil · HCl could not increase its absolute distribution volume in the lung. Significant change of the K p value was not recognized in other organs. Therefore, it seemed that this distribution effect might specifically occur in the lung. No change of the K p value of verapamil · HCl in the brain by the concomitant use of GSO 3 Na also suggested that GSO 3 Na did not become a substrate of P-gp. Tegafur is mainly used for gastrointestinal carcinoma, so that the rectum, colon and stomach were added to the heart, lung, brain, liver, kidney and spleen as screening organs in the case of examination of the tissue to plasma concentration ratio of tegafur. No significant effect on the K p value of tegafur by the concomitant use of GSO 3 Na was recognized in any organ, however.
A protein binding experiment was also performed to determine the distribution promotion mechanism of verapamil · HCl in the lung. However, GSO 3 Na did not show any influence on the protein binding of verapamil · HCl, therefore, the protein binding was not a factor in this distribution promotion mechanism. Rick et al. reported that lidocaine, which bound to a 1 acid glycoprotein in the blood, inhibited the protein binding of verapamil · HCl. 29) Verapamil · HCl mainly binds to a 1 acid glycoprotein in the blood and an acidic compound like GSO 3 Na mainly binds to the albumin. Thus, our result that GSO 3 Na did not exert any influence on the protein binding of verapamil · HCl is adequate.
In general, an intravenously administered drug must pass through the plasma membrane for distribution in the tissue, and one of the factors which affect the membrane transport of the drug is its octanol/water partition coefficient. In the previous case, 18) the partition coefficient of TPS was enhanced by the concomitant use of GSO 3 Na and simultaneously the partition coefficient of GSO 3 Na also increased. It seemed that the change of the partition coefficient was closely related to the mechanism of the promoted distribution of TPS. In this paper, the partition coefficient of verapamil · HCl also increased with the concomitant use of GSO 3 Na. However, the partition coefficient of GSO 3 Na itself simultaneously decreased significantly, compared to that of control. Verapamil · HCl is a relatively lipid soluble drug (the partition coefficient is ca. 50) by nature, while GSO 3 Na is very water soluble (the partition coefficient is ca. 0.1). In this paper, it seemed that the natures of their solubility were respectively emphasized in appearance by their coexistence. One of the effects that change the partition coefficient of the compound is the salting-out effect. At first, we speculated that this effect caused the change of the partition coefficients of verapamil · HCl and GSO 3 Na. However, we used phosphate buffer solution of 50 mM (pH 7.4) in our experiment. The concentration of the drug (verapamil · HCl or tegafur) and GSO 3 Na were only 1 mmol/ml (1 mM) and 1-10 mmol/ ml (1-10 mM), respectively. That is, the salt concentration of the buffer solution was 5-50-fold that of the drug or GSO 3 Na. It seems it would be very difficult under this condition for the migration of a small amount of GSO 3 Na from the water layer to the organic layer to have an effect on the partition coefficient of the drug, so, this factor of the salting-out effect would be neglected. At present it is not clear why the partition coefficient of verapamil · HCl increased with the concomitant use of GSO 3 Na, nor why that of GSO 3 Na decreased at the same time compared with control. Furthermore, if the change of the partition coefficient of verapamil · HCl causes the change of its K p value, it seems that K p values would be changed in all organs, but this was not so. Therefore, we assume that a kind of interaction between verapamil · HCl and GSO 3 Na was at work and this interaction increased the partition coefficient of verapamil · HCl, decreased that of GSO 3 Na, and also specifically caused the enhancement of K p value of verapamil · HCl in the lung. However, we have no good explanation what kind of interaction was involved or why this phenomenon occurred. Further study on the relation between the lipid solubility of these compounds and the mechanism of the distribution promotion will be made in the near future.
The effect of GSO 3 Na on the affinities of verapamil · HCl and tegafur to tissues was also examined. The results showed that no significant effect was recognized in the presence of GSO 3 Na. Therefore, it seemed that the affinities of these drugs to tissues are not related to the enhancement of their K p values.
From these facts, it seems that the high lipid solubility (oil water partition coefficient) of the active drug is a very impor-tant factor in the biodistribution promotion by the concomitant use of GSO 3 Na.
CONCLUSION
In the present study, it was determined that the K p value of verapamil · HCl in the lung significantly increased with the concomitant use of GSO 3 Na, however, this apparent promotion effect disappeared in 120 min after its administration. On the other hand, the effect of the concomitant use of GSO 3 Na on tegafur was not recognized. Comparing the effects of GSO 3 Na on verapamil · HCl and tegafur, it was speculated that a relatively high lipid soluble drug might be more affected by the concomitant use of GSO 3 Na than a lower lipid soluble drug.
It was indicated that not only drug/drug interactions but also drug/conjugated metabolite interaction are necessary to ensure the effectiveness and safety of drugs in multiple-drug therapy. It was also shown that GSO 3 Na might be a candidate as a biodistribution promoter drug.
